Asymmetric Security | $4,200,000 | (Jan 23, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Atlas Invest | $25,000,000 | (Jan 22, 2026)
Cadenza Bio
United States
- Oklahoma City
- 18/12/2023
- Seed
- $2,440,000
Cadenza Bio, Inc. was founded in 2022 to accelerate and support the development of a series of novel, non-steroidal, highly selective compounds targeting Estrogen Receptor β (ERβ). Our patented and patent-pending compounds have shown therapeutic efficacy in preclinical animal models of Multiple Sclerosis and Endometriosis.
Our goal goes beyond incremental improvements. We are dedicated to breaking the cycle of disease and, in doing so, transforming lives. We aim not only to alleviate symptoms but to halt progression, promote repair, and restore quality of life to enable total activity, empowering patients to regain control over their health.
- Industry Biotechnology Research
- Website https://www.cadenza.bio/
- LinkedIn https://www.linkedin.com/company/cadenza-bio/
Related People
Carol CurtisCo Founder
United States -
Oklahoma City, Oklahoma
Knowledge and experience in technology transfer, patenting and licensing of inventions, project management, early stage venture management consulting, pre-investment risk analysis/due diligence and venture capital investing.
One to One Health | $12,000,000 | (Jan 22, 2026)
AiStrike | $7,000,000 | (Jan 22, 2026)
AnswersNow | $40,000,000 | (Jan 22, 2026)
Claim Health | $4,400,000 | (Jan 22, 2026)
Upscale AI(US) | $200,000,000 | (Jan 22, 2026)
Nasdaq Private Market | $37,600,000 | (Jan 22, 2026)
PraxisPro | $6,000,000 | (Jan 22, 2026)
furl | $10,000,000 | (Jan 22, 2026)